Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

According to the investigators of a newly published study on the waning of pneumococcal vaccines responses in people with inflammatory arthritis, pneumonia is a major cause of mortality in this ...

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...

Among the primary approaches are adoptive cell therapy, immune checkpoint inhibitors (ICIs), and cancer vaccines. Cancer vaccines introduce tumor antigens that activate T-cells, which then target ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting both paediatric and adult populations. This partnership extension ...

(RTTNews) - Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation pneumococcal vaccines for both pediatric and adult ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

The pneumococcal conjugate vaccine—known ... which lack support from organizations like Gavi, the vaccine alliance, and Pan American Health Organization (PAHO). Our region has been the slowest ...